Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Curetis","sponsor":"BioVersys AG","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Curetis

    Menu

    Curetis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Curetis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OpGen Subsidiary Curetis and BioVersys Sign Collaboration Agreement for Clinical Trial Support

              Details:

              BV100 is a much-needed injectable formulation of rifabutin to treat serious infections caused by Carbapenem Resistant Acinetobacter baumannii in patients with ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia and bloodstream infections.

              Lead Product(s): Rifabutin

              Therapeutic Area: Infections and Infectious Diseases Product Name: BV100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: BioVersys AG

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY